ChronicleBio builds the chronic-disease data layer AI drug discovery lacks
Co-founder Fidji Simo tied ChronicleBio's data thesis to her own illness weeks after leaving OpenAI's full-time leadership team.
By Ryan Merket · Published
Primary source: X
Why it matters
ChronicleBio's potential moat is consented, longitudinal biological data from neglected disease populations. If the cohort works, patient recruitment and biobanking become defensible AI infrastructure.
ChronicleBio co-founder Fidji Simo (@fidjissimo) said the path from artificial intelligence to treatments for complex chronic illnesses runs through a resource medicine still lacks: deep biological data collected from patients over time.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.